Search
Lys-plasminogen
go.drugbank.com/drugs/DB32870ExperimentalLys-plasminogen is a truncated form of natural human plasminogen.
Reproxalap
go.drugbank.com/drugs/DB16688Investigational[L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis
IP501
go.drugbank.com/drugs/DB06450ExperimentalIP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis. … The compound was developed by Indevus Pharmaceuticals.
VGV-1
go.drugbank.com/drugs/DB05328ExperimentalVGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
AT-7519
go.drugbank.com/drugs/DB08142InvestigationalIt is developed by Astex for the treatment of solid tumours and haematological malignancies.
Serotonin
go.drugbank.com/drugs/DB08839InvestigationalNutraceuticalFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
PS386113
go.drugbank.com/drugs/DB05211ExperimentalPS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.
HGTV-43
go.drugbank.com/drugs/DB05807ExperimentalHGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Tetrathiomolybdate
go.drugbank.com/drugs/DB05088InvestigationalCOPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. … Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.
Categories: Compounds used in a research, industrial, or household settingATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.